MCID: PPL021
MIFTS: 50

Papilledema

Categories: Eye diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Papilledema

MalaCards integrated aliases for Papilledema:

Name: Papilledema 11 19 75 28 53 14 71
Edema of the Optic Disc 19
Choked Disk 19

Classifications:



External Ids:

Disease Ontology 11 DOID:146
ICD9CM 34 377.0
MeSH 43 D010211
NCIt 49 C3307
SNOMED-CT 68 423341008
ICD10 31 H47.1
UMLS 71 C0030353

Summaries for Papilledema

GARD: 19 Papilledema is a condition in which increased pressure in or around the brain (intracranial pressure) causes swelling of the part of the optic nerve inside the eye (optic disc). Symptoms of increased intracranial pressure include headache or nausea and vomiting. Vision problems are not common initially, but may include short flickers of gray vision, blurred or double vision, and decreased field of vision or ability to see colors. Both eyes are usually affected. Papilledema by definition is caused by increased cranial pressure. Diagnosis includes a thorough eye exam by an ophthalmologist. Brain imaging studies (for example CT scan or MRI) are used to find the cause of the increased intracranial pressure.

MalaCards based summary: Papilledema, also known as edema of the optic disc, is related to optic papillitis and poems syndrome, and has symptoms including edema An important gene associated with Papilledema is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Innate Immune System and Response to elevated platelet cytosolic Ca2+. The drugs Lymecycline and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and endothelial, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: 75 Papilledema or papilloedema is optic disc swelling that is caused by increased intracranial pressure due... more...

Related Diseases for Papilledema

Diseases related to Papilledema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1011)
# Related Disease Score Top Affiliating Genes
1 optic papillitis 31.4 NLRP3 MOG CRP AQP4 ACE
2 poems syndrome 31.3 VEGFA MYOM2 IL6
3 hydrocephalus 30.8 VEGFA TP53 SYP SERPINA3 AQP4 ACE
4 thrombophilia due to thrombin defect 30.7 SERPINC1 F3 F2 APOH
5 thrombosis 30.3 SERPINC1 SERPINA3 JAK2 F3 F2 APOH
6 lateral sinus thrombosis 30.3 SERPINC1 F2
7 nonarteritic anterior ischemic optic neuropathy 30.2 VEGFA SERPINC1 MOG F2 CRP AQP4
8 abducens palsy 30.2 SERPINC1 MOG F2 CRP AQP4
9 intracranial hypertension 30.1 SERPINC1 IL6 F3 F2 CRP AQP4
10 cauda equina syndrome 30.1 SYP F3 F2 CRP
11 neuritis 30.0 VEGFA MOG IL6 AQP4
12 communicating hydrocephalus 30.0 SERPINA3 AQP4 ALB
13 optic neuritis 29.9 VEGFA MOG IL6 AQP4
14 arteriovenous malformation 29.9 VEGFA SERPINA3 F3 F2 ALB
15 polycythemia 29.8 VEGFA JAK2 F3 F2 CRP ACE
16 sagittal sinus thrombosis 29.8 SERPINC1 JAK2 F3 F2 CRP APOH
17 antiphospholipid syndrome 29.8 SERPINC1 F3 F2 CRP APOH
18 syphilis 29.8 CRP APOH ALB ACE
19 subdural empyema 29.8 F2 CRP
20 mastoiditis 29.8 SERPINC1 F3 F2 CRP
21 multiple cranial nerve palsy 29.8 CRP ACE
22 neurosarcoidosis 29.7 MOG CRP AQP4 ACE
23 hypertensive retinopathy 29.7 VEGFA CRP ALB ACE
24 macular dystrophy, dominant cystoid 29.7 VEGFA IL6 ACE
25 polyarteritis nodosa 29.7 IL6 CRP APOH
26 choroiditis 29.7 VEGFA CRP ACE
27 brucellosis 29.7 NLRP3 IL6 CRP
28 brain cancer 29.6 VEGFA TP53 SYP STAT3 AQP4
29 cardiomyopathy, familial hypertrophic, 20 29.6 F2 ALB
30 vasculitis 29.6 SERPINA3 IL6 CRP APOH
31 hemangioblastoma 29.6 VEGFA SYP STAT3 JAK2
32 macular retinal edema 29.6 VEGFA IL6 ALB ACE
33 granulomatous angiitis 29.6 CRP ACE
34 hyperhomocysteinemia 29.6 SERPINC1 F2 CRP APOH ALB
35 acute retrobulbar neuritis 29.5 MOG AQP4 ACE
36 neuroretinitis 29.5 VEGFA MOG CRP AQP4 ACE
37 radiculopathy 29.5 IL6 IL1R1 CRP
38 vascular cancer 29.5 VEGFA TP53 SYP SERPINA3
39 chorioretinitis 29.4 VEGFA IL6 CRP ACE
40 osteosclerotic myeloma 29.4 VEGFA MYOM2 IL6
41 pulmonary emphysema 29.4 VEGFA SERPINA3 ALB
42 meningitis 29.3 VEGFA NLRP3 IL6 CRP AQP4 ALB
43 acquired immunodeficiency syndrome 29.3 TP53 IL6 CRP ALB
44 intracranial hypotension 29.3 SERPINC1 F3 F2 CRP ALB
45 hemorrhagic disease 29.3 SERPINC1 F3 F2 CRP ALB
46 castleman disease 29.3 VEGFA MYOM2 IL6 CRP
47 chronic fatigue syndrome 29.3 SERPINA3 IL6 CRP
48 diastolic heart failure 29.3 IL6 CRP ACE
49 posterior uveitis 29.2 VEGFA IL6 ACE
50 middle east respiratory syndrome 29.2 IL6 CRP ACE

Graphical network of the top 20 diseases related to Papilledema:



Diseases related to Papilledema

Symptoms & Phenotypes for Papilledema

UMLS symptoms related to Papilledema:


edema

GenomeRNAi Phenotypes related to Papilledema according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 ACE ALB APOH AQP4 ARSB CRP
2 no effect GR00402-S-2 10.2 ACE ALB APOH AQP4 CRP F2

MGI Mouse Phenotypes related to Papilledema:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 ACE ALB APOH AQP4 ARSB CRP
2 nervous system MP:0003631 10.43 AQP4 ARSB F2 F3 IL1R1 IL6
3 growth/size/body region MP:0005378 10.37 ACE AQP4 ARSB F2 F3 IL1R1
4 renal/urinary system MP:0005367 10.32 ACE ALB AQP4 ARSB IL1R1 IL6
5 cellular MP:0005384 10.32 ACE ALB ARSB F2 F3 IL1R1
6 muscle MP:0005369 10.31 ALB ARSB F2 F3 IL1R1 IL6
7 immune system MP:0005387 10.31 ACE ALB AQP4 CRP F2 F3
8 cardiovascular system MP:0005385 10.3 ACE ALB AQP4 ARSB CRP F2
9 normal MP:0002873 10.29 ALB F2 F3 IL1R1 JAK2 NLRP3
10 behavior/neurological MP:0005386 10.28 ACE AQP4 ARSB F2 F3 IL1R1
11 liver/biliary system MP:0005370 10.26 ACE ALB IL1R1 IL6 JAK2 NLRP3
12 neoplasm MP:0002006 10.25 ACE ALB F3 IL1R1 IL6 JAK2
13 endocrine/exocrine gland MP:0005379 10.21 ACE ALB AQP4 F2 IL1R1 IL6
14 adipose tissue MP:0005375 10.15 ACE ARSB F2 IL1R1 IL6 NLRP3
15 digestive/alimentary MP:0005381 10.15 ALB AQP4 F2 IL1R1 IL6 NLRP3
16 respiratory system MP:0005388 10.07 AQP4 ARSB F2 F3 IL1R1 IL6
17 reproductive system MP:0005389 10.06 ACE AQP4 ARSB F2 IL6 JAK2
18 hematopoietic system MP:0005397 10.03 ACE AQP4 ARSB F2 F3 IL1R1
19 vision/eye MP:0005391 10 AQP4 ARSB F3 IL1R1 IL6 MOG
20 mortality/aging MP:0010768 9.8 ACE ALB APOH AQP4 F2 F3
21 integument MP:0010771 9.36 F2 F3 IL1R1 IL6 JAK2 MYOM2

Drugs & Therapeutics for Papilledema

Drugs for Papilledema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lymecycline Approved, Investigational Phase 4 992-21-2
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
10
Ranibizumab Approved Phase 4 347396-82-1
11
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
12
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
13
Methylprednisolone Acetate Phase 4 584547
14 Angiogenesis Inhibitors Phase 4
15 Pharmaceutical Solutions Phase 4
16 Endothelial Growth Factors Phase 4
17 Mitogens Phase 4
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3 3680
19
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 3003 5743
20 Anti-Inflammatory Agents Phase 2, Phase 3
21 Hormones Phase 2, Phase 3
22 Hormone Antagonists Phase 2, Phase 3
23 glucocorticoids Phase 2, Phase 3
24 Antineoplastic Agents, Hormonal Phase 2, Phase 3
25 Antiemetics Phase 2, Phase 3
26 HIV Protease Inhibitors Phase 2, Phase 3
27 BB 1101 Phase 2, Phase 3
28 Gastrointestinal Agents Phase 2, Phase 3
29
protease inhibitors Phase 2, Phase 3
30 Antirheumatic Agents Phase 1, Phase 2
31 Interleukin 1 Receptor Antagonist Protein Phase 1, Phase 2
32
Levoleucovorin Approved, Experimental, Investigational Phase 1 68538-85-2, 58-05-9, 73951-54-9 149436 6006
33
Flavin mononucleotide Approved, Investigational Phase 1 146-17-8 643976
34
Mecobalamin Approved, Investigational Phase 1 13422-55-4
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
36
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 1 65-23-6 1054
37
Pyridoxal phosphate Approved, Investigational, Nutraceutical Phase 1 54-47-7 1051
38
Cyanocobalamin Approved, Nutraceutical Phase 1 68-19-9 24892734 16212801 44176380
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1 22737-96-8, 68-26-8 5280382 445354
40
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1 83-88-5 493570
41
Cobalamin Experimental Phase 1 13408-78-1 6857388
42 Folate Phase 1
43 Vitamins Phase 1
44 Vitamin B9 Phase 1
45 Vitamin B6 Phase 1
46 Trace Elements Phase 1
47
Vitamin B2 Phase 1
48 Vitamin B12 Phase 1
49 Vitamin B Complex Phase 1
50 Vitamin B 6 Phase 1

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
2 Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) When Placed Within the Lower Eye Lid Canaliculus or Both the Upper and Lower Canaliculi for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker. Unknown status NCT04501367 Phase 4 Dexamethasone Intracanalicular Insert, 0.4 mg;Prednisone acetate 1%
3 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
4 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
5 Ozurdex in Treatment of Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
6 Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe Completed NCT03071055 Phase 2 Ranibizumab Injection [Lucentis]
7 A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease Terminated NCT00069329 Phase 1, Phase 2 anakinra
8 Evaluation of the Feasibility, Safety and Efficacy of Venous Stenting for Internal Jugular Vein Stenosis Unknown status NCT03373292 Phase 1
9 B-Complex: A Nutraceutical SANS Countermeasure Recruiting NCT05366933 Phase 1 Vitamin B-Complex Supplement
10 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858
11 Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema Unknown status NCT02410148
12 Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Unknown status NCT03273179
13 Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination Unknown status NCT02992262
14 Determination of Normal Measures of Optic Nerve Sheath Diameter in Children Unknown status NCT03178760
15 Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases Completed NCT03753893
16 Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery Completed NCT01847638 Prolensa (bromfenac 0.07%);Ilevro (nepafenac 0.3%)
17 LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes Completed NCT01318941 Ranibizumab
18 Retinal Nerve Fibre Layer in Uveitic Secondary Glaucoma Completed NCT01170481
19 Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy Completed NCT03490318
20 Precise High Resolution MRI to Increase Accuracy and Gain Confidence to Diagnose Patients With Optic Disc Edema Recruiting NCT04448613
21 Investigation of Retinal Pathology in Eye Diseases Using High Resolution Optical Coherence Tomography (High-Res-OCT) Recruiting NCT05130385
22 A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema Available NCT01487044 Macugen (Pegaptanib Sodium)
23 Resistant Diabetic Macular Edema and Suprachoroidal Injection Not yet recruiting NCT04690608 Early Phase 1 Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

Search NIH Clinical Center for Papilledema

Genetic Tests for Papilledema

Genetic tests related to Papilledema:

# Genetic test Affiliating Genes
1 Papilledema 28

Anatomical Context for Papilledema

Organs/tissues related to Papilledema:

MalaCards : Eye, Brain, Endothelial, Spinal Cord, Pineal, Retina, Lymph Node

Publications for Papilledema

Articles related to Papilledema:

(show top 50) (show all 3341)
# Title Authors PMID Year
1
A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. 53 62
7536209 1995
2
Ophthalmoplegia in Patient With Papilledema. 62
36255092 2022
3
External-internal cranial expansion to treat patients with craniocerebral disproportion due to post-shunt craniosynostosis: a case series. 62
36456748 2022
4
Interdisciplinary Protocol for the Management of Vision-Threatening Papilledema. 62
35439211 2022
5
Visual outcomes in idiopathic intracranial hypertension in children. 62
34283970 2022
6
Features of Idiopathic Intracranial Hypertension on MRI With MR Elastography: Prospective Comparison With Control Individuals and Assessment of Postintervention Changes. 62
35822642 2022
7
Multimodal imaging in differential diagnosis between papilledema and choroidal neovascularization associated with morning glory syndrome. 62
36464666 2022
8
Can Lumbar Puncture Be Safely Deferred in Patients With Mild Presumed Idiopathic Intracranial Hypertension? 62
34860748 2022
9
[Misleading diagnosis of papilledema]. 62
35179624 2022
10
Bilateral dural arteriovenous fistula diagnosed with neurovascular ultrasonography. 62
36465029 2022
11
Progress and Challenges in Bacterial Meningitis: A Review. 62
36472590 2022
12
Acute Bilateral Vision Loss Following Unilateral Optic Nerve Sheath Fenestration. 62
35604378 2022
13
Behavioral, Learning Skills, and Visual Improvement in Crouzon Syndrome Patient Following Late Posterior Vault Distraction Osteogenesis. 62
36000757 2022
14
Hyphema and secondary glaucoma as a presenting complaint in a dog with chronic lymphocytic leukemia. 62
36415701 2022
15
Risk factors for the development of secondary intracranial hypertension in acute cerebral venous thrombosis. 62
36445465 2022
16
Longstanding overt ventriculomegaly diagnosed in adolescents, not adults: a pediatric case report. 62
36427075 2022
17
Venous Sinus Stenting for Low Pressure Gradient Stenoses in Idiopathic Intracranial Hypertension. 62
35960743 2022
18
Expanding the clinical spectrum of idiopathic intracranial hypertension. 62
36444979 2022
19
Neuroimaging in the diagnosis and treatment of intracranial pressure disorders. 62
36333629 2022
20
The yield of ophthalmoscopy as a screening tool for intracranial pathology in pediatric headache. 62
36401633 2022
21
An overview of peripapillary hyperreflective ovoid mass-like structures. 62
36094020 2022
22
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension: A Case Report. 62
36261298 2022
23
[Bilateral papilledema as presenting sign of neurocysticercosis]. 62
35599057 2022
24
Ocular Findings of Cryptococcal Meningitis in Previously Health Adults. 62
36255081 2022
25
The Clinical Profile of Unilateral and Bilateral Optic Disc Swelling in a Tertiary Center in Northern Malaysia. 62
36415408 2022
26
Cerebrospinal Fluid Shunting for Idiopathic Intracranial Hypertension: A Systematic Review, Meta-Analysis, and Implications for a Modern Management Protocol. 62
35916578 2022
27
Idiopathic Intracranial Hypertension and Endoscopic Optic Nerve Sheath Fenestration. 62
36452828 2022
28
De Novo Presentation of Idiopathic Intracranial Hypertension (IIH) Associated With COVID-19 Infection. 62
36147772 2022
29
Comparison of Idiopathic Intracranial Hypertension Patients With and Without Anemia. 62
36255106 2022
30
Stenting versus medical treatment for idiopathic intracranial hypertension: a matched-control study. 62
36202600 2022
31
Transorbital sonography: A non-invasive bedside screening tool for detection of pseudotumor cerebri syndrome. 62
35469442 2022
32
Clinical and prognostic importance of craniospinal elastance and pressure volume index in pediatric pseudotumor cerebri syndrome. 62
36190524 2022
33
A clinico-radiological study of deep cerebral venous thrombosis. 62
35462575 2022
34
Multimodal imaging of the course of retinal changes in acute posterior multifocal placoid pigment epitheliopathy with bilateral retinal detachment: a case report. 62
36207677 2022
35
Ophthalmological Findings in Youths With a Newly Diagnosed Brain Tumor. 62
36107418 2022
36
Peripapillary hyperreflective ovoid masslike structures in a pediatric population referred for suspected papilledema. 62
36189468 2022
37
Lupus Anticoagulant-Hypoprothrombinemia Syndrome and Pseudotumor Cerebri as an Initial Presentation of Systemic Lupus Erythematosus in a 16-Year-Old Male Patient: A Case Report and Literature Review. 62
36207805 2022
38
Endophthalmitis diagnosis supported by bedside ultrasound. 62
36176502 2022
39
[FROM OPTIC NERVE EDEMA TO POLYSOMNOGRAPHY - ANOTHER WAY TO DIAGNOSE OBSTRUCTIVE SLEEP APNEA]. 62
36315213 2022
40
Bilateral papilledema associated with retinal hemorrhagic appearance as earliest sign of spinal cord tumor. 62
36214152 2022
41
Inappropriate Use of the Term "Papilledema" in the Medical Literature: A Systematic Review of Case Reports across Specialties. 62
36195254 2022
42
The use of OCT to detect signs of intracranial hypertension in patients with sagittal suture synostosis: Reference values and correlations. 62
35972534 2022
43
The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia. 62
34270382 2022
44
Early and long-term skull growth after surgical correction for sagittal synostosis in relation to the occurrence of papilledema. 62
36053310 2022
45
Discriminating Between Papilledema and Optic Disc Drusen Using 3D Structural Analysis of the Optic Nerve Head. 62
36175153 2022
46
Giant Colloid Cyst. 62
35803569 2022
47
[Ocular symptoms in cerebellitis caused by COVID-19 : Cerebellitis, a less noticed disease with neuro-ophthalmological findings]. 62
36169716 2022
48
Acute Headache in Adults: A Diagnostic Approach. 62
36126007 2022
49
Ocular Findings in Children with Headache. 62
36125107 2022
50
Meningeal Metastasis Causing Chronic Subdural Hematoma in a Cancer Patient with Bilateral Papilledema and Suspected Cerebral Venous Thrombosis: A Case Report. 62
35453161 2022

Variations for Papilledema

Expression for Papilledema

Search GEO for disease gene expression data for Papilledema.

Pathways for Papilledema

Pathways related to Papilledema according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 ARSB CRP F2 IL1R1 IL6 JAK2
2
Show member pathways
12.97 VEGFA TP53 SERPINC1 SERPINA3 JAK2 F3
3
Show member pathways
12.49 TP53 STAT3 JAK2 IL6 F2
4
Show member pathways
12.29 SERPINC1 IL6 F2 ALB
5
Show member pathways
12.24 TP53 JAK2 IL6 IL1R1
6 12.09 VEGFA TP53 STAT3 IL6
7 11.96 ALB IL6 STAT3 VEGFA
8 11.87 TP53 IL6 IL1R1 AQP4
9 11.8 STAT3 SERPINA3 JAK2 CRP
10 11.74 VEGFA STAT3 JAK2 IL6
11
Show member pathways
11.72 NLRP3 JAK2 F3
12 11.7 VEGFA SYP MOG
13
Show member pathways
11.69 STAT3 JAK2 IL6 IL1R1
14 11.67 VEGFA TP53 IL6
15 11.63 STAT3 JAK2 IL6
16 11.59 VEGFA TP53 STAT3 JAK2 IL6
17 11.57 STAT3 JAK2 IL6
18 11.51 VEGFA JAK2 IL6
19 11.43 STAT3 IL6 IL1R1
20 11.41 IL6 STAT3 TP53 VEGFA
21
Show member pathways
11.31 NLRP3 IL6 ACE
22 11.28 STAT3 JAK2 IL6 CRP
23 11.12 VEGFA NLRP3 IL6
24 11.03 NLRP3 IL1R1 F2
25
Show member pathways
10.87 VEGFA STAT3 SERPINA3 JAK2 IL6
26 10.84 STAT3 JAK2 IL6
27
Show member pathways
10.73 VEGFA STAT3 JAK2 CRP
28 10.63 TP53 STAT3
29 10.17 STAT3 JAK2

GO Terms for Papilledema

Cellular components related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.74 VEGFA SERPINC1 SERPINA3 NLRP3 IL6 IL1R1
2 external side of plasma membrane GO:0009897 9.7 MOG IL1R1 F3 F2 AQP4 ACE

Biological processes related to Papilledema according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.26 CRP IL1R1 IL6 NLRP3 SERPINA3 STAT3
2 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.99 JAK2 IL6 F2
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.97 IL6 JAK2 TP53 VEGFA
4 cytokine-mediated signaling pathway GO:0019221 9.97 STAT3 JAK2 IL6 IL1R1 F3
5 positive regulation of interleukin-1 beta production GO:0032731 9.86 STAT3 NLRP3 JAK2 IL6
6 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.83 VEGFA TP53
7 regulation of vascular endothelial growth factor production GO:0010574 9.8 IL6 AQP4
8 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.73 VEGFA ACE
9 negative regulation of primary miRNA processing GO:2000635 9.71 STAT3 IL6
10 hemostasis GO:0007599 9.63 SERPINC1 F3 F2
11 interleukin-6-mediated signaling pathway GO:0070102 9.63 STAT3 JAK2 IL6
12 regulation of blood coagulation GO:0030193 9.26 SERPINC1 F2 APOH
13 acute-phase response GO:0006953 9.23 SERPINA3 IL6 F2 CRP

Molecular functions related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.64 VEGFA TP53 SYP STAT3 SERPINC1 NLRP3
2 protease binding GO:0002020 9.56 TP53 SERPINC1 IL1R1 F3

Sources for Papilledema

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....